国产创新药全面突破，全球首款无激素儿童湿疹药在上海诞生

Core Viewpoint - A technological revolution in the global pediatric eczema treatment field is being led by Chinese pharmaceutical companies, exemplified by Shanghai Zedman Pharmaceutical Technology Co., Ltd. with its innovative non-hormonal eczema medication, Zeli Mei Cream, which sets a new benchmark for Chinese innovative drugs globally [1][4]. Company Summary - Shanghai Zedman Pharmaceutical Technology Co., Ltd. has developed Zeli Mei Cream, the world's first non-hormonal eczema medication suitable for children aged 2 to 12, addressing a significant gap in the safety of pediatric medications [4]. - The company has invested over 350 million yuan in the development of Zeli Mei and has secured 12 domestic and international patents [4]. - Zedman is recognized as a rising star among local innovative pharmaceutical companies, with its chairman, Dr. Chen Genghui, being a prominent figure in the AhR field and the inventor of the globally first innovative drug in this area [3][4]. Industry Summary - The Chinese innovative drug sector is transitioning from a follower to a leader in the global pharmaceutical landscape, with the value of domestic pharmaceutical companies accelerating [2]. - In 2024, the external licensing transaction value of Chinese innovative drugs is projected to reach $12.7 billion, with a growth rate exceeding 40% for three consecutive years [2]. - The success of Zeli Mei Cream is indicative of a broader trend in the Chinese pharmaceutical industry, where local companies are making significant breakthroughs across various therapeutic areas, including oncology and dermatology [3]. Market Demand - There are approximately 35 million children suffering from eczema in China, with the condition significantly impacting their physical and mental well-being [5]. - The treatment landscape for pediatric eczema has been limited, with about 65% of mild to moderate eczema patients relying on hormonal ointments, which can lead to adverse effects in 42% of cases [6][8]. - A significant majority (80%) of parents prefer non-hormonal medications for their children, highlighting a strong market demand for alternatives like Zeli Mei Cream [9]. Clinical Value - Zeli Mei Cream has demonstrated rapid efficacy, with clinical data showing an 83.9% response rate in children and significant improvement in eczema severity within eight weeks of treatment [8]. - The medication offers a safe alternative to traditional hormonal treatments, with most adverse reactions being mild and transient [8].